MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (1794)	10/22/2007 6:38:06 AM
From: Icebrg	Read Replies (1) of 1826

MGI Pharma downgraded to "hold" Thursday, October 18, 2007 10:15:23 AM ET Brean Murray, Carret & Co NEW YORK, October 18 (newratings.com) - Analyst Jonathan Aschoff of Brean Murray downgrades MGI Pharma (MOGN.NAS) to "hold," while revising his estimates for the company. In a research note published this morning, the analyst mentions that the company has reported its 3Q07 GAAP EPS marginally short of the consensus. MGI Pharma's total product revenues grew 21% sequentially due to favourable reimbursement for Aloxi and lower-than-expected expenses, the analyst says. The downgrade in the rating is based on valuation, Brean Murray adds. The EPS estimate for 2007 has been reduced from $0.53 to -$0.14. The EPS estimate for 2008 has been raised from $0.96 to $1.29.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next